0.1% 사이클로스포린이 유리체절제술로 인한 안구건조증상에 미치는 효과 = Effect of 0.1% Cyclosporin on Dry Eye Symptom by Pars Plana Vitrectomy

다국어 초록 (Multilingual Abstract)

Purpose : This study evaluated whether topical cyclosporine A (CsA) 0.1% improves postoperative dry-eye symptoms after combined pars plana vitrectomy (PPV) and cataract surgery for idiopathic epiretinal membrane (ERM)
Methods : We conducted a single-center, single-surgeon, retrospective chart review of 40 eyes undergoing phacoemulsification with intraocular lens implantation and PPV with ERM peeling. Patients were allocated to two postoperative regimens: Group 1 received 1% prednisolone acetate tapered and discontinued at 5 weeks plus CsA 0.1% for 2 months; Group 2 received 1% prednisolone acetate for 2 months. Outcomes were assessed preoperatively and at 1 and 2 months postoperatively. The primary outcome was change in the Ocular Surface Disease Index (OSDI). Secondary outcomes included best-corrected visual acuity (BCVA, logMAR), intraocular pressure (IOP), noninvasive tear breakup time (NIBUT), lipid layer thickness (LLT), tear meniscus height (TMH), blink pattern, and central macular thickness (CMT). Repeated-measures ANOVA with Bonferroni correction (p<0.016) was used.
Results : In a total of 40 eyes, both groups showed significant improvements over time in BCVA (p=0.002), OSDI (p=0.005), and CMT (p=0.016). A significant time-by-group interaction was observed for OSDI (p=0.012). Post hoc analyses revealed greater OSDI improvement in Group 1 from 1 to 2 months and from baseline to 2 months (p=0.002 and p=0.015, respectively), and OSDI was significantly lower in Group 1 at 2 months (p=0.019). There were no significant between-group differences over time in IOP, NIBUT, LLT, TMH, or blink pattern. No cases of endophthalmitis or other severe adverse events requiring secondary intervention were observed.
Conclusion : Functionally, early tapering of topical steroid by 5 weeks with adjunctive CsA 0.1% for 2 months after combined PPV–cataract surgery was associated with greater improvement in dry-eye symptoms (OSDI) at 2 months compared with extended steroid use alone, without compromising safety or macular outcomes. This strategy may offer a steroid-sparing, symptom-focused approach to postoperative ocular surface management following ERM surgery.

목차 (Table of Contents)

• (Abstract)
• Ⅰ. 서 론 1
• Ⅱ. 대상 및 방법 2
• Ⅲ. 결 과 4
• Ⅳ. 고 찰 10
• Ⅴ. 참고문헌 13